FibroGen Stock Price. Everything You Need To Know About The FibroGen Stock!
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. The company is headquartered in San Francisco, California and currently employs 592 full-time employees. The company went IPO on 2014-11-14. The firm is engaged in discovering, developing and commercializing a pipeline of therapeutics. The company applies its capabilities in hypoxia-inducible factor (HIF) biology, 2-oxoglutarate enzymology, and connective tissue growth factor (CTGF) biology to advance medicines for the treatment of anemia, fibrotic disease, and cancer. The Company’s product Roxadustat is an oral small molecule inhibitor of HIF-prolyl hydroxylase activity for the treatment of anemia caused by chronic kidney disease (CKD). The company is also developing Roxadustat for anemia associated with myelodysplastic syndromes. The company also develops Roxadustat for the treatment of chemotherapy-induced anemia (CIA). Pamrevlumab, an anti-CTGF human monoclonal antibody for the treatment of idiopathic pulmonary fibrosis (IPF), locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Its Roxadustat is approved in China, Europe and Japan for the treatment of anemia in CKD.
FibroGen Stock Price. Everything You Need To Know About The FibroGen Stock! performance
- Employees 592
- Company HQ San Francisco
- Website https://www.fibrogen.com/
- FGEN Asset Type Common Stock
- FGEN Market Capitalization 102.7M
- Earnings Per Share -2.92
- Dividends Per Share None
- Dividend Date None
- Quarterly Earnings Growth 0.536
Are you an investor from Malaysia, Thailand, Indonesia, or Vietnam looking to invest in the global stock market? Look no further than FibroGen! FibroGen is a renowned biopharmaceutical company focused on developing transformative therapies for serious unmet medical needs. With its innovative approach and groundbreaking research, FibroGen has garnered attention from investors worldwide. Now, with Zorion’s investment platform, retail investors from Malaysia, Thailand, Indonesia, and Vietnam can easily invest in FibroGen and take advantage of the potential growth opportunities it offers. Access investment insights, recommendations, and educational resources on Zorion to make informed decisions and enhance your investment knowledge. Start investing in FibroGen today and be a part of its remarkable journey.
